No CV safety signals with fremanezumab treatment for migraine
04 Jun 2020
Patients using the CGRP* blocker fremanezumab for migraine treatment need not worry about cardiovascular (CV) safety of the drug, as pooled data from three phase III trials showed no safety signals for CV events with the treatment, even in those with a CV medical history.
Challenging the status quo: The need for a new gastric acid suppressor
03 Jun 2020;
For decades, the treatment of acid-related disorders have been limited to conventional acid suppressants. However, as Dr Daphne Ang (Changi General Hospital, Singapore) explains, clinicians can now maximise acid suppression through newer acid suppressants through potassium competitive inhibition.